Indications and uses
Tc 99m Glucoheptonate may be used to image the kidney and brain and to assess renal and brain perfusion.
Tc 99m Glucoheptonate may be used to image the kidney and brain and to assess renal and brain perfusion.
Dear Medical Professional,
Per your order, we have compounded Glucoheptonate as a sterile freeze-dried mixture. The characteristics of this preparation are
AnazaoHealth supplies compounded Glucoheptonate for the preparation of Tc 99m Glucoheptonate. Each vial contains 50 mg calcium glucoheptonate and 0.6 mg tin metal as stannous chloride. The vial is back filled with inert gas and may contain a partial vacuum.
When injected intravenously, Technetium Tc 99m Glucoheptonate is rapidly cleared from the blood. In patients with normal renal function, less than 15% of the initial activity remains in the blood after one hour. About 40% of the injected dose is excreted in the urine in one hour, while about 70% is excreted in 24 hours. In patients with renal disease, the blood clearance and urinary excretion of the radiopharmaceutical are delayed.
Up to 15% of the injected dose is retained in the kidneys. The renal retention is greater in the cortex than in the medulla. The radiopharmaceutical may be bound to the proximal convoluted tubules, which are located primarily in the renal cortex.
Technetium Tc 99m Glucoheptonate tends to accumulate in intracranial lesions that are associated with excessive neovascularity or an altered blood-brain barrier. The drug does not accumulate in the choroid plexus or salivary glands.
Tc 99m Glucoheptonate may be used to image the kidney and brain and to assess renal and brain perfusion.
Preparation of Technetium Tc 99m Glucoheptonate is done by the following aseptic procedure:
This preparation should be stored at room temperature before and after reconstitution.
Figure 1
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 51808-213-01 | 2019-11-27 | C162847 | 48780-1 | 9855d018-e1ad-cd31-e053-dbdaa90ab51a | Glucoheptonate |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 51808-213-01 | Glucoheptonate | 1 in 1 KIT | INJECTION, POWDER, LYOPHILIZED, | 1 | 2 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| CALCIUM GLUCEPTATE | ACTIVE INGREDIENT | L11651398J | 2 | |
| CALCIUM GLUCEPTATE | ACTIVE MOIETY | L11651398J | 2 | |
| STANNOUS CHLORIDE | INACTIVE INGREDIENT | 1BQV3749L5 | 2 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 51808-213 | 51808-213-01 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| CALCIUM GLUCEPTATE | L11651398J | ACTIB |
| STANNOUS CHLORIDE | 1BQV3749L5 | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| STANNOUS CHLORIDE | STANNOUS CHLORIDE | 1BQV3749L5 | INJECTION / INTRAVENOUS | 3.4 mg | ||
| STANNOUS CHLORIDE | STANNOUS CHLORIDE | 1BQV3749L5 | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 0.25 mg | ||
| STANNOUS CHLORIDE | STANNOUS CHLORIDE | 1BQV3749L5 | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | 0.08 mg | ||
| STANNOUS CHLORIDE | STANNOUS CHLORIDE | 1BQV3749L5 | INJECTION, POWDER, FOR SOLUTION / INTRADERMAL | 0.08 mg | ||
| STANNOUS CHLORIDE | STANNOUS CHLORIDE | 1BQV3749L5 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 0.42 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| fb2f24ff-01b1-4afe-9a24-dfa98fa1f047 | ac9f0c4b-d0b0-489a-896d-a92d40f21b7e | 2012-05-23 | fb2f24ff-01b1-4afe-9a24-dfa98fa1f047 ac9f0c4b-d0b0-489a-896d-a92d40f21b7e |
Adverse event summaries are temporarily unavailable. Other product information remains available.